BRPI0418427A - formulações farmacêuticas de matriz semi-sólida - Google Patents

formulações farmacêuticas de matriz semi-sólida

Info

Publication number
BRPI0418427A
BRPI0418427A BRPI0418427-0A BRPI0418427A BRPI0418427A BR PI0418427 A BRPI0418427 A BR PI0418427A BR PI0418427 A BRPI0418427 A BR PI0418427A BR PI0418427 A BRPI0418427 A BR PI0418427A
Authority
BR
Brazil
Prior art keywords
semi
pharmaceutical formulations
solid matrix
solid
matrix pharmaceutical
Prior art date
Application number
BRPI0418427-0A
Other languages
English (en)
Inventor
Cristina Ciocca
Alessandro Martini
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Publication of BRPI0418427A publication Critical patent/BRPI0418427A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Abstract

FORMULAçõES FARMACêUTICAS DE MATRIZ SEMI-SóLIDA é descrita a dispersão farmacêutica estável sólida ou semi-sólida que compreende pelo menos um fármaco suscetível a oxidação e pouco solúvel em água como ingrediente ativo, um veículo hidrofílico, um deriva de vitamina e solúvel em água como agente antioxidante e opcionalmente outros excipientes.
BRPI0418427-0A 2004-01-30 2004-01-30 formulações farmacêuticas de matriz semi-sólida BRPI0418427A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2004/050057 WO2005074890A1 (en) 2004-01-30 2004-01-30 Semisolid matrix pharmaceutical formulations

Publications (1)

Publication Number Publication Date
BRPI0418427A true BRPI0418427A (pt) 2007-06-12

Family

ID=34833876

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418427-0A BRPI0418427A (pt) 2004-01-30 2004-01-30 formulações farmacêuticas de matriz semi-sólida

Country Status (4)

Country Link
EP (1) EP1713442A1 (pt)
BR (1) BRPI0418427A (pt)
CA (1) CA2552925A1 (pt)
WO (1) WO2005074890A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ555701A (en) 2004-12-09 2011-05-27 Insys Therapeutics Inc Room-temperature stable dronabinol formulations
SI2197429T1 (sl) * 2007-09-03 2016-09-30 Nanotherapeutics, Inc. Sestavki iz delcev za vnos slabo topnih zdravil
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
WO2009129297A1 (en) * 2008-04-15 2009-10-22 Schering Corporation Semi-solid oral pharmaceutical compositions
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
WO2012063498A2 (ja) * 2010-11-12 2012-05-18 富士化学工業株式会社 新規なエキセメスタン固体分散体
CN110638767B (zh) * 2019-10-12 2021-09-10 山东省食品发酵工业研究设计院 一种维生素e固体片剂及其制备方法
CN114948901B (zh) * 2022-05-06 2023-04-21 郑州大学第一附属医院 一种协同治疗乳腺癌的依西美坦纳米粒、制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
CA2302735A1 (en) * 1998-07-14 2000-01-27 Em Industries, Inc. Microdisperse drug delivery systems
CA2471572A1 (en) * 2001-12-28 2003-07-17 Ivax Research, Inc. Taxane based compositions and methods of use

Also Published As

Publication number Publication date
CA2552925A1 (en) 2005-08-18
EP1713442A1 (en) 2006-10-25
WO2005074890A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
BR9808581A (pt) Estabilização de benzimidazóis sensìveis a ácido com combinações de aminoácido/ciclodextrina
ZA200709251B (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
BRPI0413927B8 (pt) composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
CR11493A (es) Sistema de administracion vaginal
HN2000000267A (es) Oxazolidinonas substituidas y su uso
AR048963A1 (es) Formulaciones de interferon de hidrogel de poloxamero
BR0212475A (pt) Composições farmacêuticas
ATE450252T1 (de) Arzneimittel-mikroteilchen
WO2007014124A3 (en) High drug load formulations and dosage forms
WO2008067164A3 (en) Solid pharmaceutical dosage formulations
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
GT200500349A (es) Formulaciones de benzoxazoles substituidos
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
BRPI0418427A (pt) formulações farmacêuticas de matriz semi-sólida
HK1116047A1 (en) Anthelmintic composition
PT1150686E (pt) Matriz directamente compressivel para libertacao controlada de doses diarias unitarias de claritromicina
UY27341A1 (es) Formulación farmacéutica de sabor enmascarado y procedimiento para su preparación.
PE20050443A1 (es) Formulaciones farmaceuticas transdermicas
ES2147163B1 (es) Una composicion farmaceutica con actividad reguladora de la expresion de las moleculas de adhesion.
BRPI0715809A2 (pt) Agente terapêutico para a aceleração da restauração do nervo espinhal compreendendo grelina, seus derivados ou substâncias capazes de atuar sobre o ghs-r1a como ingrediente ativo.
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
DE60319983D1 (de) Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A, 5A, 6A E 7A ANUIDADES(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.